All In Biotech

Free tool

FAERS Monitor: Rhapsido

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 218436 or its brand name (Rhapsido, Remibrutinib). Reports on generic versions are filed under their own applications.

Reports

1,354

Serious

267

20% of reports

Hospitalization

43

Death reported

1

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • urticaria186
  • petechiae185
  • drug ineffective148
  • contusion130
  • pruritus105
  • headache77
  • heavy menstrual bleeding59
  • nausea58
  • off label use57
  • condition aggravated53
  • chronic spontaneous urticaria44
  • rash40
  • fatigue39
  • cough36
  • product dose omission issue34

Reports by year received

View as table
YearReports
20249
2025234
20261,111

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,805 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
chronic spontaneous urticariaSignal44613.0455.725,281
petechiaeSignal185280.2244.750,307
heavy menstrual bleedingSignal59102.579.85,795
contusionSignal13021.017.82,464
urticariaSignal18617.315.12,853
pruritusSignal1054.23.5262
condition aggravatedSignal532.72.156
cough362.01.417
headache771.91.533
product dose omission issue341.81.311
drug ineffective1481.71.549
rash401.41.15
nausea581.10.91
off label use571.00.80
fatigue390.80.62

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.